,i  #aae? ,,congress  #b;d ,session  ,h4
 ,r4 #fadb  ,,9 ,,! ,,h\se ,,(          
,,repres5tatives  ,june #ai1 #bjah,mr4  
,doggett introduc$ ! foll[+ bill2 :i* 0 
ref]r$ to ! ,committee on ,en]gy &      
,comm]ce  ,a ,,bill  ,to au?orize a jo9t
 action plan & report on drug wa/e4  #a4
 ,%ort title ,?is ,act may be cit$ z !  
,r$uc+ ,drug ,wa/e ,act ( #bjah4  #b4   
,jo9t action plan & report on drug wa/e 
7a7 ,jo9t action plan ,! ,secret>y (    
,heal? & ,human ,s]vices1 %all develop a
 jo9t action plan1 9 consultation )     
/akehold]s su* z heal? c>e provid]s &   
pati5t advocates 7includ+ relevant      
,f$]al advisory committees71 t--  7#a7  
utilizes data f ,m$ic>e claims on h[ mu*
 ( a s+le-use drug 0 n adm9i/]$1 comp>+ 
s+le-use vial sizes 9 o!r sett+s su* z  
to o!r c\ntries' heal? c>e sy/ems1 &    
?r\gh analysis dur+ ! drug approval     
process ( alt]native vial size safety & 
efficacy1 to r$uce drug wa/e & bett]    
manage co/s2  7#b7 includes quantifiable
 metrics & specific timel9es to adopt   

diff]5t vial sizes 9 addition to ^?     
curr5tly approv$ & m>ket$ 9 ! ,unit$    
,/ates 9 ord] to significantly r$uce !  
am\nt ( drug disc>ds1 or wa/e1 f        
s+le-use vials2 &  7#c7 includes options
 = h[ to bett] manage co/s1 includ+ new 
te*nologies relat$ to capture & /orage1 
:ile ensur+ pati5t access4  7b7 ,report 
,n lat] ?an #a ye> aft] ! date (        
enactm5t ( ?is ,act1 ! ,secret>y (      
,heal? & ,human ,s]vices %all submit to 
,congress ! jo9t action plan describ$ 9 
subsection 7a7 & a report conta9+       
options = any legislative action ne$$ to
 r$uce drug wa/e & bett] manage co/s4